Lung Cancer Detection Program
Early Detection of Lung Cancer
Phase 1Active
Key Facts
About PrognomiQ
PrognomiQ is a clinical-stage biotech company with a mission to transform early detection and treatment through its proprietary multi-omics platform. Founded in 2020 as a spinout from Seer Inc., the company leverages unprecedented scale in proteomic data generation, combined with other 'omics' layers, to unlock novel biological insights for diagnostic development. Its strategy is to translate these discoveries into commercial diagnostic tests, positioning it within the competitive early cancer detection landscape. The company is publicly traded, providing capital markets access to fund its ambitious R&D agenda.
View full company profileTherapeutic Areas
Other Early Detection of Lung Cancer Drugs
| Drug | Company | Phase |
|---|---|---|
| CIZ1B Biomarker Blood Test | Cizzle Biotechnology | Clinical Validation |
| LuCED® Lung Test | VisionGate | Unknown |
| ProLung | Hawkeye Bio | Pre-clinical/Clinical Validation |
| FirstLook Lung | DELFI Diagnostics | Unknown |